Stockreport

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update [Yahoo! Finance]

Alector, Inc.  (ALEC) 
Last alector, inc. earnings: 3/24 04:05 pm Check Earnings Report
PDF The trial showed that AL002 failed to meet its primary endpoint of slowing disease progression, despite sustained target engagement and pharmacodynamic responses. As a r [Read more]